Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older

NCT06118151 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

388

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza
Influenza Immunization

Interventions

BIOLOGICAL: Influenza Hemagglutinin mRNA vaccine
BIOLOGICAL: Quadrivalent Recombinant Influenza Vaccine

Sponsor

Sanofi Pasteur, a Sanofi Company